You are here: Industry Insights > Ad5-nCoV

News List

Pharmaceutical News of August | PharmaSources.com—Transaction & IPO PharmaSources/Caicai
September 23, 2020
Suzhou Vigonvita Life Sciences completed a new series of equity financing, with Qihoo 360, Share Venture, Ganzhou Qizhi Huikang, and Suzhou Meilingge becoming new shareholders of the company and the registered capital increasing to RMB5,769,231.
CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™ prnewswire
May 25, 2021
CanSinoBIO today announced that its Recombinant Novel Coronavirus Vaccine, has been granted a Good Manufacturing Practice ("GMP") certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI).
CanSino Biologics to start clinical trials of inhaled Covid-19 vaccine pharmaceutical-technology
April 21, 2021
Chinese company CanSino Biologics is set to commence clinical trials of a Covid-19 vaccine that can be administered through inhalation.
Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization prnasia
February 26, 2021
China National Medical Products Administration (NMPA) announced on February 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector).
CanSino gets COVID-19 vaccine patent from China’s IP regulator expresspharma
August 18, 2020
CanSino Biologics has won a patent approval from Beijing for its COVID-19 vaccine candidate Ad5-nCOV, reported state media, citing documents from the country’s intellectual property regulator.
First COVID-19 vaccine given green light for Phase I trial in China europeanpharmaceuticalreview
July 02, 2020
CanSino Biologics’ Ad5-nCoV vaccine, a potential COVID-19 prophylactic, has been approved for study in a Phase I clinical trial in China.
COVID-19 vaccine induces immune response in Phase I trial europeanpharmaceuticalreview
May 27, 2020
The adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine candidate safely induced T cell and antibody responses in 108 adults.
First COVID-19 vaccine human trial finds it is safe, induces immune response expresspharma
May 27, 2020
According to the study of 108 adults, the vaccine produced neutralising antibodies, and a response mediated by the immune system's T-cells against the novel coronavirus, SARS-CoV-2.
Sartorius Supports Coronavirus Vax Candidate contractpharma
March 26, 2020
BIOSTAT STR single-use bioreactor system used for the upstream preparation of the recombinant vaccine.